LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE

---

Copy For Citation

Sukgen E. A., ATALAY H. T., ÖZDEK Ş.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, vol.42, no.11, pp.2194-2202, 2022 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 42 Issue: 11
• Publication Date: 2022
• Doi Number: 10.1097/iae.0000000000003590
• Journal Name: RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
• Page Numbers: pp.2194-2202
• Keywords: retinopathy of prematurity, anti-VEGF, ranibizumab, aflibercept, bevacizumab, fundus fluorescein angiography, refractive, spectral domain optical coherence tomography, ENDOTHELIAL GROWTH-FACTOR, INTRAVITREAL BEVACIZUMAB, TYPE-1 RETINOPATHY, OCULAR GROWTH
• Gazi University Affiliated: Yes

Abstract

Purpose: To evaluate vascular maturation of retina, axial, refractive, and foveal development after anti-VEGF treatment including bevacizumab, ranibizumab, and aflibercept in infants with treatment requiring retinopathy of prematurity (ROP) in long term.